Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company pioneering receptor-targeted therapies for metabolic and endocrine disorders. This page serves as the definitive source for all official updates and analysis-worthy developments related to the company’s innovative pipeline.
Investors and industry observers will find timely, verified information spanning clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases on key programs like the thyroid receptor agonist VK2809 for NASH, dual GLP-1/GIP agonist VK2735 for obesity, and rare disease candidate VK0214 – all developed through Viking’s receptor-specific therapeutic approach.
Content is organized to highlight material events including Phase 1-3 trial results, FDA communications, patent developments, and peer-reviewed research publications. Each update is contextualized within Viking’s broader mission to address unmet needs in metabolic health through precision pharmacology.
For consistent monitoring of Viking’s advancements in liver disease and endocrine disorder treatments, bookmark this page and revisit for authoritative reporting on trial data disclosures and corporate announcements. All content adheres to strict journalistic standards for accuracy and regulatory compliance.
Viking Therapeutics (NASDAQ: VKTX) reported its Q1 2023 financial results on April 26, 2023, highlighting significant developments in its clinical pipeline. The company completed enrollment in the Phase 2b VOYAGE study of VK2809 for NASH and fibrosis, with data expected in Q2 2023. Viking also announced Phase 1 results for VK2735, showcasing up to 6% placebo-adjusted weight loss and a strong safety profile. The initiation of a Phase 1 trial for an oral formulation of VK2735 was also noted. Financially, Viking completed a public offering raising $287.5 million, enhancing its cash position to approximately $406 million. However, the net loss for the quarter increased to $19.5 million, or $0.25 per share, compared to a loss of $16.1 million, or $0.21 per share in 2022.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
